We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+23.06%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$849M
AUM Growth
-$105M
Cap. Flow
-$227M
Cap. Flow %
-26.79%
Top 10 Hldgs %
85.18%
Holding
28
New
4
Increased
5
Reduced
7
Closed
8

Top Buys

Rank Stock Value
1
PTCT icon
PTC Therapeutics
PTCT
+$53.2M
2
KERX
Keryx Biopharmaceuticals Inc
KERX
+$43.8M
3
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$21M
4
LJPC
La Jolla Pharmaceutical Company
LJPC
+$17M
5
PACB icon
Pacific Biosciences
PACB
+$15.5M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$91.9M
2
UTHR icon
United Therapeutics
UTHR
+$86.9M
3
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$69.5M
4
CLVS
Clovis Oncology, Inc.
CLVS
+$48.3M
5
PCRX icon
Pacira BioSciences
PCRX
+$44.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMRN
1
Amarin Corp
AMRN
$298M
$100M 11.79%
1,241,214
-11,405
-0.9% -$709K
GMED icon
2
Globus Medical
GMED
$10.9B
$94M 11.07%
2,835,000
-100,000
-3% -$3.14M
MYGN icon
3
Myriad Genetics
MYGN
$507M
$84.4M 9.95%
3,267,487
+291,131
+10% +$6.18M
AAAP
4
DELISTED
Advanced Accelerator Applications S.A.
AAAP
$73M 8.6%
1,869,507
+557,652
+43% +$21M
PTCT icon
5
PTC Therapeutics
PTCT
$6.26B
$72.3M 8.52%
+3,946,009
New +$53.2M
ATRC icon
6
AtriCure
ATRC
$2.04B
$69.1M 8.14%
2,849,185
-37,169
-1% -$790K
CORT icon
7
Corcept Therapeutics
CORT
$12.7B
$68.5M 8.07%
5,804,340
+634,700
+12% +$6.9M
LJPC
8
DELISTED
La Jolla Pharmaceutical Company
LJPC
$59.9M 7.06%
2,012,519
+591,777
+42% +$17M
CLVS
9
DELISTED
Clovis Oncology, Inc.
CLVS
$51M 6.01%
544,843
-789,624
-59% -$48.3M
KERX
10
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$50.6M 5.97%
+7,005,041
New +$43.8M
TVTX icon
11
Travere Therapeutics
TVTX
$5.33B
$47.3M 5.57%
2,438,540
+306,400
+14% +$5.56M
CVRS
12
DELISTED
CORINDUS VASCULAR ROBOTICS, INC
CVRS
$28.1M 3.31%
15,114,872
– –
SPPI
13
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$15.1M 1.77%
+2,020,583
New +$13.2M
PACB icon
14
Pacific Biosciences
PACB
$460M
$13.6M 1.61%
+3,832,713
New +$15.5M
VCEL icon
15
Vericel Corp
VCEL
$2.43B
$8.47M 1%
2,566,084
-416,856
-14% -$1.14M
ANIP icon
16
ANI Pharmaceuticals
ANIP
$1.83B
$6.69M 0.79%
143,003
– –
ADMA icon
17
ADMA Biologics
ADMA
$2.01B
$4.71M 0.56%
1,273,933
– –
BIOL
18
DELISTED
Biolase, Inc.
BIOL
$1.12M 0.13%
92
-9
-9% -$134K
SPNE
19
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$618K 0.07%
53,627
-34,500
-39% -$323K
SBBP
20
DELISTED
Strongbridge Biopharma plc.
SBBP
$72K 0.01%
10,000
– –
ACHC icon
21
Acadia Healthcare
ACHC
$2.62B
– –
-310,666
Closed -$13.5M
PCRX icon
22
Pacira BioSciences
PCRX
$1.06B
– –
-972,535
Closed -$44.3M
UTHR icon
23
United Therapeutics
UTHR
$26.2B
– –
-642,168
Closed -$86.9M
ACOR
24
DELISTED
Acorda Therapeutics
ACOR
– –
-5,162
Closed -$13M
MNK
25
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
– –
-1,558,944
Closed -$69.5M
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q2 2017 Portfolio in Review

As of Q2 2017, Consonance Capital Management held 28 positions worth $849M, down 11% from $954M the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Consonance Capital Management withdrew a net $227M in Q2 2017, closing 8 positions and reducing 7 holdings. Its most notable exit was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $91.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

Against the trend, Consonance Capital Management opened a new position in PTC Therapeutics worth $72.3M.

  • Consonance Capital Management's largest Q2 2017 buy was PTC Therapeutics: 3,946,009 shares worth $72.3M.
  • Consonance Capital Management added most to Advanced Accelerator Applications S.A. in Q2 2017, an estimated $21M increase.
  • Consonance Capital Management's biggest Q2 2017 reduction was Clovis Oncology, Inc., cutting an estimated $48.3M.
  • Consonance Capital Management fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2017, selling an estimated $91.9M.
  • Consonance Capital Management's ten largest holdings make up 85% of its $849M portfolio in Q2 2017.
  • Consonance Capital Management opened 4 new positions and closed 8 in Q2 2017.
  • Consonance Capital Management's portfolio value fell 11% quarter-over-quarter to $849M.

Based on Consonance Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.